Substrate Remodelling and Targeted Ablation in AF
STRATA-AF
Understanding Substrate Evolution in Persistent Atrial Fibrillation to Develop Tailored Ablation Strategies
1 other identifier
interventional
160
1 country
1
Brief Summary
Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting millions worldwide and causing symptoms such as palpitations, fatigue and breathlessness. It also increases the risk of stroke and heart failure, so effective treatment is essential. A treatment for AF involves catheter ablation, a minimally invasive procedure where problematic areas of the heart are targeted using controlled energy. This is done by passing wires called catheters, through blood vessels at the top of the leg all the way to the heart. However, this isn't effective for everyone and approximately half of patients experience a return of AF despite treatment. In this researcher-led study at St Bartholomew's Hospital , the investigators will use a method called electroanatomical mapping to make a 3D picture of the left atrium, the heart's upper left chamber. To make this picture more detailed, information will be collected - such as how strong electrical signals are (voltage), how fast and in which direction they travel through the heart to describe abnormal areas and areas of scar within the heart. Information will also be gathered about the routes electricity takes and the nerve activity in the heart muscle. These detailed maps will help to understand why AF can continue indefinitely in some people, why ablation works for some people and not others, and improve how ablations are done to make them more effective. All participants will undergo catheter ablation with these mapping methods integrated into the procedure. If AF recurs, patients will be invited for a second ablation targeting specific abnormal areas depending on the amount of scar found. This will be standardised across patients. Patients will be followed for 12 months, with structured visits at 3, 6, 9 and 12 months and 48-hour ECG recorders at 6 and 12 months. By tracking how the heart's structure and electrical behaviour evolve, the aim is to to see if map-guided ablation reduces the need for further procedures, lowers healthcare costs and improves quality of life. Ultimately, this study will provide clear, reproducible insights into AF mechanisms and yield practical guidance so clinicians can predict who will benefit from standard ablation treatment and who may require extra, map-guided treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2025
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2025
CompletedFirst Posted
Study publicly available on registry
July 2, 2025
CompletedStudy Start
First participant enrolled
November 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 18, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 18, 2030
November 18, 2025
November 1, 2025
4 years
June 24, 2025
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Assessment of Electrical, Structural and Autonomic Remodelling in Persistent Atrial Fibrillation
A primary objective of this study is to delineate the remodelling changes that occur in persistent atrial fibrillation and to utilise these to develop tailored ablation strategies.
4 years
Establish a Predictive Model to Idenitfy Which Patients are Responders to Pulmonary Vein Isolation Alone and Who Will Require Further Tailored Ablation Strategies
Based on clinical data approximately only 50% of patients with persistent atrial fibrillation who undergo pulmonary vein isolation remain in sinus rhythm. A main aim of the study is to develop a method to identify which patients will respond to pulmonary vein isolation alone and who will require further tailored ablation strategies.
24 months
To Assess if Ablation of Rate Dependent Conduction Velocity Slowing Sites Improves Freedom from Atrial Fibrillation
All patients who recur after their initial ablation will be invited to undergo a repeat ablation procedure. All patients will undergo ganglionic plexi ablation and reisolation their pulmonary veins. Those who have low voltage zones of more than 30% of their total left atrium will undergo further ablation of rate dependent conduction velocity slowing sites.
5 years
Secondary Outcomes (1)
Develop Personalised Electrical Atrial Models
5 years
Study Arms (2)
Minimal Low Voltage Zones Group
ACTIVE COMPARATORThese are patients who've had recurrence of AF after their first ablation and less than 30% of their atria is comprised of low voltage zones. They will undergo autonomic ganglionic plexi site ablation combined with pulmonary vein re-isolation.
Significant Low Voltage Zones Group
ACTIVE COMPARATORThese are patients who've had recurrence of AF after their first ablation and greater than 30% of their atria is comprised of low voltage zones. They will undergo targeted ablation of conduction slowing sites in addition to ganlionic plexi site ablation and pulmonary vein reisolation.
Interventions
The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.
Sites where ganglionix plexi have been found will be ablated.
Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation
Eligibility Criteria
You may qualify if:
- Able and willing to provide written informed consent
- Age: 18 years or older
- Clinical diagnosis: Persistent atrial fibrillation
- Treatment status: Scheduled to undergo first-time catheter ablation for persistent AF
You may not qualify if:
- Inability or unwillingness to provide informed consent
- Under 18 years of age
- Previous left atrial ablation for AF or other atrial arrhythmias
- Any clinical contraindications to undergoing AF catheter ablation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
St Bartholomew's Hospital
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2025
First Posted
July 2, 2025
Study Start
November 7, 2025
Primary Completion (Estimated)
November 18, 2029
Study Completion (Estimated)
August 18, 2030
Last Updated
November 18, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share